12 news items
Takeda To Present Long-Term Data From Phase 3 ADVANCE-CIDP 3 Clinical Trial Of HYQVIA In Patients With Chronic Inflammatory Demyelinating Polyneuropathy At PNS Annual Meeting
TAK
18 Jun 24
) with Recombinant Human Hyaluronidase] in patients with chronic inflammatory demyelinating polyneuropathy (CIDP). Results showed favorable long-term safety
Takeda Presents Long-Term Data from Phase 3 ADVANCE-CIDP 3 Clinical Trial of HYQVIA® in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) at PNS Annual Meeting
TAK
18 Jun 24
Hyaluronidase] in patients with chronic inflammatory demyelinating polyneuropathy (CIDP). Results showed favorable long-term safety and tolerability of HYQVIA
Takeda Signs Option Agreement With Ascentage Pharma For Exclusive License Of Olverembatinib; Potential Third-Generation BCR-ABL TKI For CML And Other Hematological Cancers; License Excludes Mainland China, Hong Kong, Macau, Taiwan, And Russia
TAK
14 Jun 24
, Taiwan and Russia− Olverembatinib Has the Potential to Address Significant Unmet Need for Patients with Chronic Myeloid Leukemia Following
Takeda Signs Option Agreement with Ascentage Pharma to Enter into Exclusive Global License for Olverembatinib, a Third-Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI)
TAK
14 Jun 24
the Potential to Address Significant Unmet Need for Patients with Chronic Myeloid Leukemia Following Treatment with Currently Approved TKIs
HEALWELL AI's Pentavere Announces Partnership with Takeda to Support Rare Disease Real-World Evidence Analysis for Patients living with Hereditary Angioedema
TAK
6 Jun 24
, the Company is developing and commercializing advanced clinical decision support systems that can help healthcare providers detect rare and chronic diseases
2qfoxxxhf7b6
TAK
3 Jun 24
over 8 weeks of treatment.*
NT1 is a chronic, rare neurological central disorder of hypersomnolence caused by a significant loss
stafknq6pis5o71r4w422gimefd9e542ww3bwtmri9r8kjqq4qyvfalgwv
TAK
3 Jun 24
.*
NT1 is a chronic, rare neurological central disorder of hypersomnolence caused
ewuaan427mrvjmeyfvz8px06zofxhqse4miiq
TAK
31 May 24
for more patients around the world."
cTTP is an ultra-rare, chronic blood clotting disorder caused
m2rlr680hyg439qz8zlnnxzgir6 o2fkiuwht3
SCLX
TAK
14 May 24
and chronic pain, today announced that the 45-day review period for the U.S. Federal Trade Commission and U.S. Department of Justice to comment
4isxzrx0tp oqhx559yuwq1b5r1t76i
TAK
18 Apr 24
).8 Both UC and CD are chronic, relapsing, remitting, inflammatory conditions of the gastrointestinal tract
zf1tqgojitd 45jtxy9ny2p94oplbyja97flvx
TAK
27 Mar 24
IBD is a lifelong condition characterized by chronic inflammation in the gastrointestinal
7wr x1r0r668jumh
TAK
26 Mar 24
cTTP is an Ultra-rare Blood Clotting Disorder Associated with Life-Threatening Acute Events and Debilitating Chronic
- Prev
- 1
- Next